MPs were told in December that UK patient involvement in clinical trials will diminish post-Brexit making manufactures less likely to invest here.
They were also told that unlocking the potential of patient data held by the NHS may be enough to persuade the pharmaceutical industry to continue to look to the UK for involvement in developing new drugs and mitigate any disadvantages from leaving the EU.
Faculty of Pharmaceutical Medicine have also warned MPs that leaving the EU would damage research.
The UK may run the risk of becoming less attractive to drug companies looking to test their drugs and invest.
How to make most use of the NHS to create more clinical research?
